Carsten‐Oliver Schulz

752 total citations
20 papers, 554 citations indexed

About

Carsten‐Oliver Schulz is a scholar working on Oncology, Molecular Biology and Hematology. According to data from OpenAlex, Carsten‐Oliver Schulz has authored 20 papers receiving a total of 554 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Oncology, 6 papers in Molecular Biology and 5 papers in Hematology. Recurrent topics in Carsten‐Oliver Schulz's work include Cancer Treatment and Pharmacology (6 papers), Multiple Myeloma Research and Treatments (4 papers) and Bone health and treatments (3 papers). Carsten‐Oliver Schulz is often cited by papers focused on Cancer Treatment and Pharmacology (6 papers), Multiple Myeloma Research and Treatments (4 papers) and Bone health and treatments (3 papers). Carsten‐Oliver Schulz collaborates with scholars based in Germany, United States and Estonia. Carsten‐Oliver Schulz's co-authors include Kurt Possinger, Jan Eucker, Chuanbing Zang, Orhan Sezer, Ulrike Heider, Ivana Zavrski, Christian Jakob, Claudia Fleissner, Anne C. Regierer and Martin Kaiser and has published in prestigious journals such as Blood, Annals of Oncology and European Journal of Pharmacology.

In The Last Decade

Carsten‐Oliver Schulz

20 papers receiving 547 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Carsten‐Oliver Schulz Germany 13 283 235 170 66 61 20 554
Florence Namour Belgium 14 194 0.7× 188 0.8× 99 0.6× 17 0.3× 16 0.3× 29 646
Laura M. Rosenberg United States 6 303 1.1× 639 2.7× 42 0.2× 27 0.4× 83 1.4× 8 980
Nita Fisher United Kingdom 8 181 0.6× 237 1.0× 15 0.1× 25 0.4× 156 2.6× 9 520
W. Jens Zeller Germany 17 217 0.8× 222 0.9× 224 1.3× 5 0.1× 51 0.8× 36 632
Jacqueline Ming Liu Taiwan 15 361 1.3× 192 0.8× 28 0.2× 12 0.2× 165 2.7× 26 825
Mark DeMario United States 14 402 1.4× 437 1.9× 82 0.5× 4 0.1× 94 1.5× 25 809
Vanessa T. Garrido United States 16 294 1.0× 296 1.3× 93 0.5× 4 0.1× 181 3.0× 26 697
Yael Zimra Israel 13 92 0.3× 260 1.1× 52 0.3× 8 0.1× 38 0.6× 21 392
Xueying Wang China 8 212 0.7× 260 1.1× 35 0.2× 5 0.1× 128 2.1× 29 683
Mathieu Schaff France 9 101 0.4× 111 0.5× 351 2.1× 4 0.1× 36 0.6× 11 663

Countries citing papers authored by Carsten‐Oliver Schulz

Since Specialization
Citations

This map shows the geographic impact of Carsten‐Oliver Schulz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Carsten‐Oliver Schulz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Carsten‐Oliver Schulz more than expected).

Fields of papers citing papers by Carsten‐Oliver Schulz

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Carsten‐Oliver Schulz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Carsten‐Oliver Schulz. The network helps show where Carsten‐Oliver Schulz may publish in the future.

Co-authorship network of co-authors of Carsten‐Oliver Schulz

This figure shows the co-authorship network connecting the top 25 collaborators of Carsten‐Oliver Schulz. A scholar is included among the top collaborators of Carsten‐Oliver Schulz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Carsten‐Oliver Schulz. Carsten‐Oliver Schulz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Haanen, J.B.A.G., Andréas Mackensen, Christian Koenecke, et al.. (2021). LBA1 BNT211: A phase I/II trial to evaluate safety and efficacy of CLDN6 CAR-T cells and CARVac-mediated in vivo expansion in patients with CLDN6+ advanced solid tumors. Annals of Oncology. 32. S1392–S1392. 7 indexed citations
2.
3.
Schulz, Carsten‐Oliver, Julien Mazières, Johan Vansteenkiste, et al.. (2016). Efficacy, safety and predictive biomarker results from a randomized phase II study comparing atezolizumab vs docetaxel in patients with advanced NSCLC (POPLAR). 39. 104–104. 1 indexed citations
4.
Zang, Chuanbing, Jan Eucker, Piet Habbel, et al.. (2015). Targeting multiple tyrosine kinase receptors with Dovitinib blocks invasion and the interaction between tumor cells and cancer-associated fibroblasts in breast cancer. Cell Cycle. 14(8). 1291–1299. 14 indexed citations
5.
Habbel, Piet, Annika Kurreck, Carsten‐Oliver Schulz, et al.. (2015). Cisplatin Plus Ifosfamide with/without Etoposide as Salvage Treatment in Heavily-pre-treated Patients with Metastatic Breast Cancer.. PubMed. 35(9). 5091–5. 3 indexed citations
6.
Eucker, Jan, Chuanbing Zang, Xinhua Li, et al.. (2014). TKI258, a multi-tyrosine kinase inhibitor is efficacious against human infant/childhood lymphoblastic leukemia in vitro.. PubMed. 34(9). 4899–907. 4 indexed citations
7.
Liu, Hongyu, Christian Schölz, Chuanbing Zang, et al.. (2012). Metformin and the mTOR inhibitor everolimus (RAD001) sensitize breast cancer cells to the cytotoxic effect of chemotherapeutic drugs in vitro.. PubMed. 32(5). 1627–37. 88 indexed citations
8.
Schölz, Christian, Anne C. Regierer, Peter Martus, et al.. (2012). The mTOR inhibitor everolimus in combination with carboplatin in metastatic breast cancer--a phase I trial.. PubMed. 32(8). 3435–41. 15 indexed citations
9.
Brunnberg, Uta, Michael Möhr, Richard Noppeney, et al.. (2011). Induction therapy of AML with ara-C plus daunorubicin versus ara-C plus gemtuzumab ozogamicin: a randomized phase II trial in elderly patients. Annals of Oncology. 23(4). 990–996. 31 indexed citations
10.
Liu, Hongyu, Chuanbing Zang, Anne C. Regierer, et al.. (2011). The mTOR inhibitor RAD001 sensitizes tumor cells to the cytotoxic effect of carboplatin in breast cancer in vitro.. PubMed. 31(9). 2713–22. 16 indexed citations
11.
Regierer, Anne C., Carsten‐Oliver Schulz, Bernd Flath, et al.. (2011). Breast Cancer-Associated Thrombotic Microangiopathy. Breast Care. 6(6). 441–445. 15 indexed citations
12.
Liu, Hongyu, Chuanbing Zang, Anna Emde, et al.. (2008). Anti-tumor effect of honokiol alone and in combination with other anti-cancer agents in breast cancer. European Journal of Pharmacology. 591(1-3). 43–51. 107 indexed citations
13.
Heider, Ulrike, Martin Kaiser, Christian Müller, et al.. (2006). Bortezomib increases osteoblast activity in myeloma patients irrespective of response to treatment. European Journal Of Haematology. 77(3). 233–238. 122 indexed citations
14.
Schmid, Peter, V. Heilmann, Carsten‐Oliver Schulz, et al.. (2005). Gemcitabine as prolonged infusion and vinorelbine in anthracycline and/or taxane pretreated metastatic breast cancer: a phase II study. Journal of Cancer Research and Clinical Oncology. 131(9). 568–574. 12 indexed citations
15.
16.
Heider, Ulrike, Martin Kaiser, Christian Müller, et al.. (2005). Treatment of Bortezomib Increases Osteoblast Function in Patients with Multiple Myeloma.. Blood. 106(11). 3457–3457. 4 indexed citations
17.
Dieing, Annette, Carsten‐Oliver Schulz, Peter Schmid, et al.. (2004). Orbital metastases in breast cancer: report of two cases and review of the literature. Journal of Cancer Research and Clinical Oncology. 130(12). 745–748. 40 indexed citations
18.
Schmid, Peter, Carsten‐Oliver Schulz, Annette Dieing, et al.. (2004). Primary chemotherapy with gemcitabine, liposomal doxorubicin and docetaxel in patients with locally advanced breast cancer: results of a phase I trial. Anti-Cancer Drugs. 16(1). 21–29. 14 indexed citations
19.
Jakob, Christian, Ivana Zavrski, Ulrike Heider, et al.. (2003). Serum levels of carboxy-terminal telopeptide of type-I collagen are elevated in patients with multiple myeloma showing skeletal manifestations in magnetic resonance imaging but lacking lytic bone lesions in conventional radiography.. PubMed. 9(8). 3047–51. 26 indexed citations
20.
Schmid, P., Annette Dieing, V. Heilmann, et al.. (2003). 376 Primary chemotherapy with gemcitabine (G), myocet (M) and docetaxel (T): results of a phase I/II trial. European Journal of Cancer Supplements. 1(5). S115–S116. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Florence Namour Breakdown of academic impact, for papers by Laura M. Rosenberg Breakdown of academic impact, for papers by Nita Fisher Breakdown of academic impact, for papers by W. Jens Zeller Breakdown of academic impact, for papers by Jacqueline Ming Liu Breakdown of academic impact, for papers by Mark DeMario Breakdown of academic impact, for papers by Vanessa T. Garrido Breakdown of academic impact, for papers by Yael Zimra Breakdown of academic impact, for papers by Xueying Wang Breakdown of academic impact, for papers by Mathieu Schaff
Rankless by CCL
2026